Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 5 , Pages 885-900 , October 2008

Health economics of osteoporosis

  • Fredrik Borgström, PhD (Adjunct Lecturer)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +46 8 545 28 544; Fax: +46 8 545 28 549.

References 

  1. Drummond MF. Methods for the economic evaluation of health care programmes. 3rd edn.. Oxford: Oxford University Press; 2005;
  2. Fleurence RL, Iglesias CP, Torgerson DJ. Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporosis International. 2006;17(1):29–40
  3. Zethraeus N, Borgstrom F, Strom O, et al. Cost-effectiveness of the treatment and prevention of osteoporosis – a review of the literature and a reference model. Osteoporosis International. 2007;18(1):9–23
  4. Johannesson M. Theory and methods of economic evaluation of health scare. Dordrecht: Kluwer Academic Publishers; 1996;
  5. Burstrom K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Quality of Life Research. 2001;10(7):621–635
  6. Borgstrom F, Johnell O, Kanis JA, et al. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporosis International. 2006;17(10):1459–1471
  7. Zethraeus N, Ben Sedrine W, Caulin F, et al. Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporosis International. 2002;13(11):841–857
  8. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Medical Decision Making. 1993;13(4):322–338
  9. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. Journal of Bone and Mineral Research. 2005;20(7):1185–1194
  10. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ (Clinical Research Ed.). 1996;312(7041):1254–1259
  11. Bagger YZ, Tanko LB, Alexandersen P, et al. The long-term predictive value of bone mineral density measurements for fracture risk is independent of the site of measurement and the age at diagnosis: results from the prospective epidemiological risk factors study. Osteoporosis International. 2005;1–7
  12. Jönsson B, Hedbrant J & Johnell O. A Computer Simulation Model to Analyse the Cost-effectiveness of Fracture Prevention of Osteoporosis. EFI Research Paper No. 6525, 1993.
  13. Johannesson M, Jonsson B. Economic evaluation of osteoporosis prevention. Health Policy. 1993;24(2):103–124
  14. Earnshaw SR, Graham CN, Ettinger B, et al. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Current Medical Research and Opinion. 2007;23(10):2517–2529
  15. Jansen J, Gaugris G, Bergman G, et al. Cost-effectiveness of fosavance in the treatment and prevention of osteoporosis in the United Kingdom. Osteoporosis International. 2006;17(Suppl. 1):96
  16. Kanis JA, Alexandre JM, Bone HG, et al. Study design in osteoporosis: a European perspective. Journal of Bone and Mineral Research. 2003;18(6):1133–1138
  17. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38(6):922–928
  18. Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporosis International. 2007;18(6):711–719
  19. Fayers PM, Hand DJ. Generalisation from phase III clinical trials: survival, quality of life, and health economics. Lancet. 1997;350(9083):1025–1027
  20. Simon G, Wagner E, Vonkorff M. Cost-effectiveness comparisons using ‘real world’ randomized trials: the case of new antidepressant drugs. Journal of Clinical Epidemiology. 1995;48(3):363–373
  21. Schousboe JT, Ensrud KE, Nyman JA, et al. Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score >−2.5 for alendronate therapy: a modeling study. Journal of Clinical Densitometry. 2006;9(2):133–143
  22. Schwenkglenks M, Lippuner K. Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. Osteoporosis International. 2007;18(11):1481–1491
  23. Strom O, Borgström F, Kanis J et al. Incorporating adherence in health economic modeling of osteoporosis. Osteoporos International, in press, doi: 10.1007/s00198-008-0644-9.
  24. Weycker D, Macarios D, Edelsberg J, et al. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporosis International. 2007;18(3):271–277
  25. Siris ES, Genant HK, Laster AJ, et al. Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Osteoporosis International. 2007;18(6):761–770
  26. Zethraeus N, Stromberg L, Jonsson B, et al. The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthopaedica Scandinavica. 1997;68(1):13–17
  27. Dolan P, Torgerson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporosis International. 1998;8(6):611–617
  28. Zethraeus N, Gerdtham UG. Estimating the costs of hip fracture and potential savings. International Journal of Technology Assessment in Health Care. 1998;14(2):255–267
  29. Reginster JY, Gillet P, Ben Sedrine W, et al. Direct costs of hip fractures in patients over 60 years of age in Belgium. PharmacoEconomics. 1999;15(5):507–514
  30. De Laet CE, van Hout BA, Burger H, et al. Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporosis International. 1999;10(1):66–72
  31. Gabriel SE, Tosteson AN, Leibson CL, et al. Direct medical costs attributable to osteoporotic fractures. Osteoporosis International. 2002;13(4):323–330
  32. Borgstrom F, Zethraeus N, Johnell O, et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporosis International. 2006;17(5):637–650
  33. Ström O, Borgstrom F, Zethraeus N, et al. Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthopaedica. 2008;79(2):269–280
  34. Salkeld G, Cameron ID, Cumming RG, et al. Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ (Clinical Research Ed.). 2000;320(7231):341–346
  35. Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. Journal of Bone and Mineral Research. 2000;15(7):1384–1392
  36. Tosteson AN, Gabriel SE, Grove MR, et al. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporosis International. 2001;12(12):1042–1049
  37. Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocrine Reviews. 2002;23(4):517–523
  38. Gabriel SE, Kneeland TS, Melton LJ, et al. Health-related quality of life in economic evaluations for osteoporosis: whose values should we use?. Medical Decision Making. 1999;19(2):141–148
  39. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporosis International. 2005;16(Suppl. 2):S3–S7
  40. Brazier JE, Green C, Kanis JA. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporosis International. 2002;13(10):768–776
  41. Tidermark J, Zethraeus N, Svensson O, et al. Quality of life related to fracture displacement among elderly patients with femoral neck fractures treated with internal fixation. Journal of Orthopaedic Trauma. 2003;17(Suppl. 8):S17–S21
  42. Zethraeus N, Borgström F, Johnell O, et al. Costs and quality of life associated with osteoporosis related fractures - results from a Swedish survey. Working paper series in economics and finance. 512. Stockholm: Stockholm School of Economics; 2002;
  43. Kanis JA, Johnell O, Oden A, et al. Intervention thresholds for osteoporosis. Bone. 2002;31(1):26–31
  44. Kanis JA, Oden A, Johnell O, et al. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporosis International. 2001;12(5):417–427
  45. Kanis JA, Johnell O, Oden A, et al. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporosis International. 2008;19(4):385–397
  46. Kanis JA, Adams J, Borgstrom F, et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone. 2008;42(1):4–15
  47. Kanis JA, Borgstrom F, Zethraeus N, et al. Intervention thresholds for osteoporosis in the UK. Bone. 2005;36(1):22–32
  48. Kanis JA, Johnell O, Oden A, et al. Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporosis International. 2005;16(1):6–14
  49. Fujiwara S, Nakamura T, Orimo H, et al. Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporosis International. 2008;19(4):429–435
  50. Dawson-Hughes B, Tosteson AN, Melton LJ, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporosis International. 2008;19(4):449–458
  51. Tosteson AN, Melton LJ, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporosis International. 2008;19(4):437–447
  52. Siminoski K, Leslie WD, Frame H, et al. Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. Journal of Clinical Densitometry. 2007;10(2):120–123
  53. Kurth AA, Pfeilschifter J. Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German guidelines update 2006. Der Orthopäde. 2007;36(7):683–690quiz 691
  54. Czerwinski E, Badurski JE, Marcinowska-Suchowierska E, et al. Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortopedia Traumatologia Rehabilitacja. 2007;9(4):337–356
  55. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International. 2008;19(4):399–428
  56. Kanis J, McCloskey E, Johansson H et al. Case finding for the management of osteoporosis with FRAX™ – assessment and intervention thresholds for the UK. Osteoporosis International, in press.

PII: S1521-690X(08)00083-3

doi: 10.1016/j.beem.2008.07.005

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 5 , Pages 885-900 , October 2008

Article Tools

* Image Usage & Resolution